Showing results (1-10 of 1,510) with videos related to
Sort By:
Pageof 151
CPT: Pharmacometrics & Systems Pharmacology|September 21, 2022
CYTOCON: The manually curated database of human in vivo cell and molecule concentrationsVladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, et al.CPT: Pharmacometrics & Systems Pharmacology|October 17, 2022
Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancerJenny-Hoa Nguyen, Daniel Epling, Nancy Dolphin, et al.CPT: Pharmacometrics & Systems Pharmacology|November 4, 2022
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumorsNageshwar Budha, Chi-Yuan Wu, Zhiyu Tang, et al.CPT: Pharmacometrics & Systems Pharmacology|October 16, 2014
Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational ModelingC S Monast, M J LazzaraCPT: Pharmacometrics & Systems Pharmacology|November 13, 2014
Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolismK Madrasi, R N Burns, C W Hendrix, et al.CPT: Pharmacometrics & Systems Pharmacology|November 27, 2014
A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic PopulationsK Gadkar, N Budha, A Baruch, et al.CPT: Pharmacometrics & Systems Pharmacology|November 5, 2015
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic AtrophyK N Le, L Gibiansky, M van Lookeren Campagne, et al.CPT: Pharmacometrics & Systems Pharmacology|November 5, 2015
Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis DrugsL Gaohua, J Wedagedera, B G Small, et al.CPT: Pharmacometrics & Systems Pharmacology|June 15, 2016
Communicating to Influence Drug Development and Regulatory Decisions: A TutorialS Mehrotra, J GobburuCPT: Pharmacometrics & Systems Pharmacology|June 15, 2016
Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIVK H Hui, S S Lee, T N LamPageof 151